Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Phase of Trial: Phase II
Latest Information Update: 10 May 2018
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 03 May 2018 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 01 Sep 2016 Planned primary completion date changed from 1 Sep 2020 to 1 Aug 2020.
- 01 Sep 2016 Status changed from not yet recruiting to recruiting.